Table 4 |
|||
|
Disease modifying anti-rheumatic drugs: biologics |
|||
| Agent |
FDA pregnancy category |
Adverse effects in human pregnancy |
Summary risk assessment |
|
|
|||
| Etanercept |
B |
No documented increased risk for structural defects |
Based on minimal data in human pregnancy, teratogenic risk is undetermined |
| Infliximab |
B |
||
| Adalimumab |
B |
||
| Rituximab |
C |
No documented increased risk for structural defects based on case report |
Based on lack of data in human pregnancy, teratogenic risk is undetermined |
| Anakinra |
B |
No available human data |
Based on lack of data in human pregnancy, teratogenic risk is undetermined |
|
|
|||
|
Chambers et al. Arthritis Research & Therapy 2006 8:215 doi:10.1186/ar1977 |
|||